Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrating community voices in the research continuum: Perspectives on a consultation service.
Evans CD, Nanda JP, Ouyang P, Bone L, Byiringiro S, Lacanienta C, Clark R, Weston C, Han HR, Terkowitz M, Bates-Hopkins B, Galiatsatos P, Xu AJ, Stevens S, Himmelfarb CR. Evans CD, et al. Among authors: xu aj. J Clin Transl Sci. 2023 Jul 28;7(1):e177. doi: 10.1017/cts.2023.600. eCollection 2023. J Clin Transl Sci. 2023. PMID: 37654776 Free PMC article.
40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy.
Moore A, Zhang Z, Fei T, Zhang L, Accomando L, Schmitt AM, Higginson DS, Mueller BA, Zinovoy M, Gelblum DY, Yerramilli D, Xu AJ, Brennan VS, Guttmann DM, Grossman CE, Dover LL, Shaverdian N, Pike LRG, Cuaron JJ, Dreyfuss A, Lis E, Barzilai O, Bilsky MH, Yamada Y. Moore A, et al. Among authors: xu aj. Neurosurgery. 2024 Mar 8. doi: 10.1227/neu.0000000000002889. Online ahead of print. Neurosurgery. 2024. PMID: 38456696
Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
Kubeczko M, Jarząb M, Gabryś D, Krzywon A, Cortez AJ, Xu AJ. Kubeczko M, et al. Among authors: xu aj. Radiother Oncol. 2024 May;194:110188. doi: 10.1016/j.radonc.2024.110188. Epub 2024 Mar 6. Radiother Oncol. 2024. PMID: 38447357 Free article. No abstract available.
Comparative Evaluation of Proton Therapy and Volumetric Modulated Arc Therapy for Brachial Plexus Sparing in the Comprehensive Reirradiation of High-Risk Recurrent Breast Cancer.
Choi JI, McCormick B, Park P, Millar M, Walker K, Tung CC, Huang S, Florio P, Chen CC, Lozano A, Hanlon AL, Fox J, Xu AJ, Zinovoy M, Mueller B, Bakst R, LaPlant Q, Braunstein LZ, Khan AJ, Powell SN, Cahlon O. Choi JI, et al. Among authors: xu aj. Adv Radiat Oncol. 2023 Aug 18;9(2):101355. doi: 10.1016/j.adro.2023.101355. eCollection 2024 Feb. Adv Radiat Oncol. 2023. PMID: 38405315 Free PMC article.
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Clinical Trial.
90 results